---
schema_version: "secwatch.filing_event.v1"
accession: "0000805928-23-000087"
form_type: "8-K"
ticker: "AXGN"
cik: "0000805928"
company_name: "Axogen, Inc."
filed_at: "2023-08-07T23:59:59+00:00"
generated_at: "2026-06-12T05:16:49.599808+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Axogen Q2 revenue $38.2M (+11% YoY); net loss narrows to $6.7M

## Summary
- Revenue $38.2M in Q2 2023, up 11% vs Q2 2022; scheduled procedures grew >20%, trauma low-single-digit.
- Net loss $6.7M ($0.16 per share) vs $7.7M loss a year ago; adjusted net loss $1.3M ($0.03 per share).
- Gross margin 81.1% (vs 81.8% YoY); cash & investments $40.8M; $3.6M capex for new Dayton processing facility.
- FY 2023 revenue guidance maintained at $154M-$159M (11-15% growth); gross margin expected ~80% for full year.
- Pilot launched Axoguard HA+ Nerve Protector; BLA submission for Avance expected Q1-Q2 2024 with target approval H1 2025.

## SEC filing metadata
- accession: 0000805928-23-000087
- form_type: 8-K
- ticker: AXGN
- cik: 0000805928
- company_name: Axogen, Inc.
- filed_at: 2023-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/805928/000080592823000087/0000805928-23-000087-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/805928/000080592823000087/axgn-20230807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000805928-23-000087
- JSON: https://secwatch.observer/filing/0000805928-23-000087.json
- Plain text: https://secwatch.observer/filing/0000805928-23-000087.txt

## Key facts
- Earnings Releases
  Axogen, Inc. updated its six months ended June 30, 2023 guidance (reaffirmed).
  - Period: six months ended June 30, 2023
  - Guidance: reaffirmed
  - Result: reported results
  source text: On July 26, 2023, Axogen, Inc. (the “Company”) issued a press release announcing its three and six months ended June 30, 2023 financial results.
  evidence_url: https://www.sec.gov/Archives/edgar/data/805928/000080592823000087/0000805928-23-000087-index.htm
- Earnings Releases
  Axogen, Inc. reported second quarter ended June 30, 2023 results: revenue $38.2 million, net income $6.7 million, EPS $0.16 per share. Guidance reaffirmed.
  - Period: second quarter ended June 30, 2023
  - Revenue: $38.2 million
  - Net income: $6.7 million
  - EPS: $0.16 per share
  - Guidance: reaffirmed
  - Result: reported results
  source text: today reported financial results and business highlights for the second quarter ended June 30, 2023. Second Quarter Financial Results and Business Highlights • Revenue was $38.2 million during the second quarter, an increase of approximately 11% over the second quarter of 2022. • The Company estimates that revenues from scheduled non-trauma procedures
  evidence_url: https://www.sec.gov/Archives/edgar/data/805928/000080592823000087/0000805928-23-000087-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.